Discovery of the HCV NS3/4A Protease Inhibitor (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization

doi:10.1021/jm060173k

Title: Discovery of the HCV NS3/4A Protease Inhibitor (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization

Full Record
Other Related Research

Authors:

Prongay, Andrew J.; Guo, Zhuyan; Yao, Nanhua; Pichardo, John; Fischmann, Thierry; Strickland, Corey; Myers, Jr., Joseph; Weber, Patricia C.; Beyer, Brian M.; Ingram, Richard; Hong, Zhi; Prosise, Winifred W.; Ramanathan, Lata; Taremi, S. Shane; Yarosh-Tomaine, Taisa; Zhang, Rumin; Senior, Mary; Yang, Rong-Sheng; Malcolm, Bruce; Arasappan, Ashok more »

(Schering-Plough)

Publication Date:: 2013-11-20

Research Org.:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Org.:: INDUSTRY

OSTI Identifier:: 1107375

Resource Type:: Journal Article

Journal Name:: J. Med. Chem.

Additional Journal Information:: Journal Volume: 50; Journal Issue: (10) ; 05, 2007

Country of Publication:: United States

Language:: ENGLISH

Citation Formats


                    Prongay, Andrew J., Guo, Zhuyan, Yao, Nanhua, Pichardo, John, Fischmann, Thierry, Strickland, Corey, Myers, Jr., Joseph, Weber, Patricia C., Beyer, Brian M., Ingram, Richard, Hong, Zhi, Prosise, Winifred W., Ramanathan, Lata, Taremi, S. Shane, Yarosh-Tomaine, Taisa, Zhang, Rumin, Senior, Mary, Yang, Rong-Sheng, Malcolm, Bruce, Arasappan, Ashok, Bennett, Frank, Bogen, Stephane L., Chen, Kevin, Jao, Edwin, Liu, Yi-Tsung, Lovey, Raymond G., Saksena, Anil K., Venkatraman, Srikanth, Girijavallabhan, Viyyoor, Njoroge, F. George, and Madison, Vincent. Discovery of the HCV NS3/4A Protease Inhibitor (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization.  United States: N. p., 2013. 
        Web.  doi:10.1021/jm060173k.

Copy to clipboard


                    Prongay, Andrew J., Guo, Zhuyan, Yao, Nanhua, Pichardo, John, Fischmann, Thierry, Strickland, Corey, Myers, Jr., Joseph, Weber, Patricia C., Beyer, Brian M., Ingram, Richard, Hong, Zhi, Prosise, Winifred W., Ramanathan, Lata, Taremi, S. Shane, Yarosh-Tomaine, Taisa, Zhang, Rumin, Senior, Mary, Yang, Rong-Sheng, Malcolm, Bruce, Arasappan, Ashok, Bennett, Frank, Bogen, Stephane L., Chen, Kevin, Jao, Edwin, Liu, Yi-Tsung, Lovey, Raymond G., Saksena, Anil K., Venkatraman, Srikanth, Girijavallabhan, Viyyoor, Njoroge, F. George, & Madison, Vincent. Discovery of the HCV NS3/4A Protease Inhibitor (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization.  United States.  doi:10.1021/jm060173k.

Copy to clipboard


                    Prongay, Andrew J., Guo, Zhuyan, Yao, Nanhua, Pichardo, John, Fischmann, Thierry, Strickland, Corey, Myers, Jr., Joseph, Weber, Patricia C., Beyer, Brian M., Ingram, Richard, Hong, Zhi, Prosise, Winifred W., Ramanathan, Lata, Taremi, S. Shane, Yarosh-Tomaine, Taisa, Zhang, Rumin, Senior, Mary, Yang, Rong-Sheng, Malcolm, Bruce, Arasappan, Ashok, Bennett, Frank, Bogen, Stephane L., Chen, Kevin, Jao, Edwin, Liu, Yi-Tsung, Lovey, Raymond G., Saksena, Anil K., Venkatraman, Srikanth, Girijavallabhan, Viyyoor, Njoroge, F. George, and Madison, Vincent. Wed .  
        "Discovery of the HCV NS3/4A Protease Inhibitor (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization".  United States.  doi:10.1021/jm060173k.

Copy to clipboard


                    
@article{osti_1107375,

  title        = {Discovery of the HCV NS3/4A Protease Inhibitor (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization},

  author       = {Prongay, Andrew J. and Guo, Zhuyan and Yao, Nanhua and Pichardo, John and Fischmann, Thierry and Strickland, Corey and Myers, Jr., Joseph and Weber, Patricia C. and Beyer, Brian M. and Ingram, Richard and Hong, Zhi and Prosise, Winifred W. and Ramanathan, Lata and Taremi, S. Shane and Yarosh-Tomaine, Taisa and Zhang, Rumin and Senior, Mary and Yang, Rong-Sheng and Malcolm, Bruce and Arasappan, Ashok and Bennett, Frank and Bogen, Stephane L. and Chen, Kevin and Jao, Edwin and Liu, Yi-Tsung and Lovey, Raymond G. and Saksena, Anil K. and Venkatraman, Srikanth and Girijavallabhan, Viyyoor and Njoroge, F. George and Madison, Vincent},

  abstractNote = {},

  doi          = {10.1021/jm060173k},

  journal      = {J. Med. Chem.},
number       = (10) ; 05, 2007,

  volume       = 50,

  place        = {United States},

  year         = {2013},

  month        = {11}

}

Copy to clipboard

Journal Article:

DOI: 10.1021/jm060173k

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

Journal Article Venkatraman, Srikanth ; Bogen, Stephane L. ; Arasappan, Ashok ; ... - J. Med. Chem.

Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-{alpha} or polyethylene glycol (PEG)-interferon-{alpha} alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitormore »« less
DOI: 10.1021/jm060325b
Stereoselective Ring-Opening Metathesis Polymerization (ROMP) of Methyl- N -(1-phenylethyl)-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylate by Molybdenum and Tungsten Initiators

Journal Article Jeong, Hyangsoo ; Ng, Victor W. L. ; Börner, Janna ; ... - Macromolecules

Ring-opening metathesis polymerization (ROMP) of methyl- N-(1-phenylethyl)-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylate (PhEtNNBE; ( S) and racemic) was researched employing six molybdenum and tungsten imido alkylidene initiators and two tungsten oxo alkylidene initiators. Of the six initiators that we introduced should yield cis,syndiotactic-poly[( S)-PhEtNNBE], two molybdenum OHMT alkylidene initiators, Mo(NR)(CHMe ₂Ph)(pyr)(OHMT) (R = 1-adamantyl (Ad) or 2,6-Me ₂C ₆H ₃ (Ar'); OHMT = O-2,6-mesityl ₂C ₆H ₃; pyr = pyrrolide), and two tungsten oxo alkylidene initiators, W(O)(CHMe ₂Ph)(2,5-dimethylpyrrolide)(PMe ₂Ph)(OR) (OR = OHMT or ( R)-OBr ₂Bitet where ( R)-Br ₂BitetOH = ( R)-3,3'-dibromo-2'-( tert-butyldimethylsilyloxy)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl-2-ol), produced essentially pure cis,syndiotactic-poly[(S)-PhEtNNBE]. Essentially pure cis,isotactic-poly[( S)-PhEtNNBE] was formed whenmore »« less
Cited by 12
DOI: 10.1021/acs.macromol.5b00264

Full Text Available
Novel Potent Hepatitis C Virus NS3 Serine Protease Inhibitors Derived from Proline-Based Macrocycles

Journal Article Chen, Kevin X. ; Njoroge, F. George ; Arasappan, Ashok ; ... - J. Med. Chem.

The hepatitis C virus (HCV) NS3 protease is essential for viral replication. It has been a target of choice for intensive drug discovery research. On the basis of an active pentapeptide inhibitor, 1, we envisioned that macrocyclization from the P2 proline to P3 capping could enhance binding to the backbone Ala156 residue and the S4 pocket. Thus, a number of P2 proline-based macrocyclic {alpha}-ketoamide inhibitors were prepared and investigated in an HCV NS3 serine protease continuous assay (K*{sub i}). The biological activity varied substantially depending on factors such as the ring size, number of amino acid residues, number of methylmore »« less
DOI: 10.1021/jm050820s
Discovery of SCH446211 (SCH6): A New Ketoamide Inhibitor of the HCV NS3 Serine Protease and HCV Subgenomic RNA Replication

Journal Article Bogen, Stephane L. ; Arasappan, Ashok ; Bennett, Frank ; ... - J. Med. Chem.

Introduction of various modified prolines at P{sub 2} and optimization of the P{sub 1} side chain led to the discovery of SCH6 (24, Table 2), a potent ketoamide inhibitor of the HCV NS3 serine protease. In addition to excellent enzyme potency (K*{sub i} = 3.8 nM), 24 was also found to be a potent inhibitor of HCV subgenomic RNA replication with IC{sub 50} and IC{sub 90} of 40 and 100 nM, respectively. Recently, antiviral activity of 24 was demonstrated with inhibition of the full-length genotype 2a HCV genome. In addition, 24 was found to restore the responsiveness of the interferonmore »« less
DOI: 10.1021/jm060077j
The prevalence of the pre-existing hepatitis C viral variants and the evolution of drug resistance in patients treated with the NS3-4a serine protease inhibitor telaprevir

Journal Article Rong, Libin ; Ribeiro, Ruy M ; Perelson, Alan S - PLoS computational biology

Telaprevir (VX-950), a novel hepatitis C virus (HCV) NS3-4A serine protease inhibitor, has demonstrated substantial antiviral activity in patients infected with HCV genotype 1. Some patients experience viral breakthrough, which has been shown to be associated with emergence of telaprevir-resistant HCV variants during treatment. The exact mechanisms underlying the rapid selection of drug resistant viral variants during dosing are not fully understood. In this paper, we develop a two-strain model to study the pre-treatment prevalence of the mutant virus and derive an analytical solution of the mutant frequency after administration of the protease inhibitor. Our analysis suggests that the rapidmore »« less
Full Text Available

Similar Records